WO2001057032A1 - C10 ester substituted taxanes as antitumor agents - Google Patents
C10 ester substituted taxanes as antitumor agents Download PDFInfo
- Publication number
- WO2001057032A1 WO2001057032A1 PCT/US2001/003623 US0103623W WO0157032A1 WO 2001057032 A1 WO2001057032 A1 WO 2001057032A1 US 0103623 W US0103623 W US 0103623W WO 0157032 A1 WO0157032 A1 WO 0157032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridyl
- thienyl
- furyl
- taxane
- alkyl
- Prior art date
Links
- 0 C[C@@](*)[C@](C(O)O[C@@](C[C@]([C@]1C)([C@](C([C@]2([C@](C3)OC2)OC(C)=O)[C@@]2(C)[C@]3O)OC(c3ccccc3)=O)O)C(C)=C1[C@@](*)C2=O)O Chemical compound C[C@@](*)[C@](C(O)O[C@@](C[C@]([C@]1C)([C@](C([C@]2([C@](C3)OC2)OC(C)=O)[C@@]2(C)[C@]3O)OC(c3ccccc3)=O)O)C(C)=C1[C@@](*)C2=O)O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
- B65D83/75—Aerosol containers not provided for in groups B65D83/16 - B65D83/74
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention is directed to novel taxanes which have exceptional utility as antitumor agents.
- Taxol itself is employed as a cancer chemotherapeutic agent and possesses a broad range of tumor-inhibiting activity. Taxol has a 2'R, 3'S configuration and the following structural formula:
- taxol and docetaxel are useful chemotherapeutic agents, there are limitations on their effectiveness, including limited efficacy against certain types of cancers and toxicity to subjects when administered at various doses. Accordingly, a need remains for additional chemotherapeutic agents with improved efficacy and less toxicity.
- taxanes which compare favorably to taxol and docetaxel with respect to efficacy as anti-tumor agents and with respect to toxicity.
- these taxanes possess an ester substituent other than formate, acetate and heterosubstituted acetate at C-10, a hydroxy substituent at C-7 and a range of C-3' substituents.
- the present invention is directed to the taxane composition, per se, to pharmaceutical compositions comprising the taxane and a pharmaceutically acceptable carrier, and to methods of administration.
- the taxanes of the present invention correspond to structure (1):
- R 2 is acyloxy
- R 7 is hydroxy
- R 9 is eto, hydroxy, or acyloxy
- R 10 is R 10a COO-
- R 10a is hydrocarbyl, substituted hydrocarbyl, or heterocyclo wherein said hydrocarbyl or substituted hydrocarbyl contains carbon atoms in the alpha and beta positions relative to the carbon of which R 10a is a substituent;
- R 14 is hydrido or hydroxy
- X 3 is substituted or unsubstituted alkyl, alkenyl, alkynyl, phenyl or heterocyclo, wherein alkyl comprises at least two carbon atoms;
- X 5 is -COX 10 , -COOX 10 , or -CONHX 10 ;
- X 10 is hydrocarbyl, substituted hydrocarbyl, or heterocyclo; Ac is acetyl; and
- R 7 , R g , and R 10 independently have the alpha or beta stereochemical configuration.
- R 2 is an ester (R 2a C(O)O-), a carbamate (R 2a R 2b NC(0)O-), a carbonate (R 2a OC(O)O-), or a thiocarbamate (R 2a SC(O)O-) wherein R 2a and R 2b are independently hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo.
- R 2 is an ester (R 2a C(O)O- ), wherein R 2a is aryl or heteroaromatic.
- R 2 is an ester (R 2a C(O)O-), wherein R 2a is substituted or unsubstituted phenyl, furyl, thienyl, or pyridyl.
- R 2 is benzoyloxy.
- R 9 is keto in one embodiment of the present invention, in other embodiments R 9 may have the alpha or beta stereochemical configuration, preferably the beta stereochemical configuration, and may be, for example, ⁇ - or ⁇ -hydroxy or ⁇ - or ⁇ -acyloxy.
- R 9 when R 9 is acyloxy, it may be an ester (R 9a C(O)O-), a carbamate (R 9a R gb NC(O)O-), a carbonate (R 9a OC(O)O-), or a thiocarbamate (R 9a SC(O)O-) wherein R 9a and R 9b are independently hydrogen, hydrocarbyl, substituted hydrocarbyl or heterocyclo.
- R 9 is an ester (R 9a C(O)O-)
- R 9a is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaromatic.
- R 9 is an ester (R 9a C(O)O-), wherein R 9a is substituted or unsubstituted phenyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl, or substituted or unsubstituted pyridyl.
- R 9 is (R ga C(O)O-) wherein R 9a is methyl, ethyl, propyl (straight, branched or cyclic), butyl (straight, branched or cyclic), pentyl, (straight, branched or cyclic), or hexyl (straight, branched or cyclic).
- R 9 is (R 9a C(O)O-) wherein R 9a is substituted methyl, substituted ethyl, substituted propyl (straight, branched or cyclic), substituted butyl (straight, branched or cyclic), substituted pentyl, (straight, branched or cyclic), or substituted hexyl (straight, branched or cyclic) wherein the substituent(s) is/are selected from the group consisting of heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, keto, acyloxy, nitro, amino, amido, thiol, ketal, acetal, ester and ether moieties, but not phosphorous containing moieties.
- R 10 is R 10a COO- wherein R 10a is (i) substituted or unsubstituted C 2 to C 8 alkyl (straight, branched or cyclic), such as ethyl, propyl, butyl, pentyl, or hexyl; (ii) substituted or unsubstituted C 2 to C 8 alkenyl (straight, branched or cyclic), such as ethenyl, propenyl, butenyl, pentenyl or hexenyl; (iii) substituted or unsubstituted C 2 to C 8 alkynyl (straight or branched) such as ethynyl, propynyl, butynyl, pentynyl, or hexynyl; (iv) substituted or unsubstituted phenyl; or (v) substituted or unsubstituted heteroaromatic such as furyl,
- R 10a is ethyl, straight, branched or cyclic propyl, straight, branched or cyclic butyl, straight, branched or cyclic pentyl, straight, branched or cyclic hexyl, straight or branched propenyl, isobutenyl, furyl or thienyl.
- R 10a is substituted ethyl, substituted propyl (straight, branched or cyclic), substituted propenyl (straight or branched), substituted isobutenyl, substituted furyl or substituted thienyl wherein the substituent(s) is/are selected from the group consisting of heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, keto, acyloxy, nitro, amino, amido, thiol, ketal, acetal, ester and ether moieties, but not phosphorous containing moieties.
- Exemplary X 3 substituents include substituted or unsubstituted C 2 to C 8 alkyl, substituted or unsubstituted C 2 to C 8 alkenyl, substituted or unsubstituted C 2 to C 8 alkynyl, substituted or unsubstituted heteroaromatics containing 5 or 6 ring atoms, and substituted or unsubstituted phenyl.
- Exemplary preferred X 3 substituents include substituted or unsubstituted ethyl, propyl, butyl, cyclopropyl, cyclobutyl, cyclohexyl, isobutenyl, furyl, thienyl, and pyridyl.
- Exemplary X 5 substituents include -COX 10 , -COOX 10 or -CONHX 10 wherein X 10 is substituted or unsubstituted alkyl, alkenyl, phenyl or heteroaromatic.
- Exemplary preferred X 5 substituents include -COX 10> -COOX 10 or -CONHX 10 wherein X 10 is (i) substituted or unsubstituted C, to C 8 alkyl such as substituted or unsubstituted methyl, ethyl, propyl (straight, branched or cyclic), butyl (straight, branched or cyclic), pentyl (straight, branched or cyclic), or hexyl (straight, branched or cyclic); (ii) substituted or unsubstituted C 2 to C 8 alkenyl such as substituted or unsubstituted ethenyl, propenyl (straight, branche
- the taxanes of the present invention correspond to structure (2):
- R 7 is hydroxy
- R 10 is R 10a COO-
- X 3 is substituted or unsubstituted alkyl, alkenyl, alkynyl, or heterocyclo, wherein alkyl comprises at least two carbon atoms;
- X 5 is -COX 10 , -COOX 10 , or -CONHX 10 ;
- X 10 is hydrocarbyl, substituted hydrocarbyl, or heterocyclo
- R 10a is hydrocarbyl, substituted hydrocarbyl, or heterocyclo wherein said hydrocarbyl or substituted hydrocarbyl contains carbon atoms in the alpha and beta positions relative to the carbon of which R 10a is a substituent;
- Bz is benzoyl
- R 10a may be substituted or unsubstituted ethyl, propyl or butyl, more preferably substituted or unsubstituted ethyl or propyl, still more preferably substituted or unsubstituted ethyl, and still more preferably unsubstituted ethyl.
- X 3 is selected from substituted or unsubstituted alkyl, alkenyl, phenyl or heterocyclo, more preferably substituted or unsubstituted alkenyl, phenyl or heterocyclo, still more preferably substituted or unsubstituted phenyl or heterocyclo, and still more preferably heterocyclo such as furyl, thienyl or pyridyl.
- R 10a and X 3 are selected from among these
- X 5 is selected from -COX 10 wherein X 10 is phenyl, alkyl or heterocyclo, more preferably phenyl.
- X 5 is selected from -COX 10 wherein X 10 is phenyl, alkyl or heterocyclo, more preferably phenyl, or X 5 is -COOX 10 wherein X 10 is alkyl, preferably t-butyl.
- X 5 is -COOX 10 wherein X 10 is tert-butyl or X 5 is -COX 10 wherein X 10 is phenyl
- X 3 is substituted or unsubstituted cycloalkyl, alkenyl, phenyl or heterocyclo, more preferably substituted or unsubstituted isobutenyl, phenyl, furyl, thienyl, or pyridyl, still more preferably unsubstituted isobutenyl, furyl, thienyl or pyridyl
- R 7a is unsubstituted ethyl or propyl, more preferably ethyl.
- X 3 is preferably cycloalkyl, isobutenyl, or heterocyclo, more preferably heterocyclo, still more preferably furyl, thienyl or pyridyl; and X 5 is preferably benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is keto and R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t- butoxycarbonyl or t-amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is keto and R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl, still more preferably t- butoxycarbonyl
- R 2 is benzoyl
- R 9 is keto and R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is hydroxy
- R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl, still more preferably t- butoxycarbonyl
- R 2 is benzoyl
- R 9 is hydroxy
- R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R g is acyloxy
- R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl, still more preferably t- butoxycarbonyl
- R 2 is benzoyl
- R 9 is acyloxy
- R 14 is hydrido.
- R 7 and R 10 may each have the beta stereochemical configuration
- R 7 and R 10 may each have the alpha stereochemical configuration
- R 7 may have the alpha stereochemical configuration while R 10 has the beta stereochemical configuration
- R 7 may have the beta stereochemical configuration while R 10 has the alpha stereochemical configuration.
- X 3 is preferably cycloalkyl, isobutenyl, phenyl, substituted phenyl such as p-nitrophenyl, or heterocyclo, more preferably heterocyclo, still more preferably furyl, thienyl or pyridyl; and X 5 is preferably benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t- butoxycarbonyl or t-amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is keto and R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl, still more preferably t- butoxycarbonyl
- R 2 is benzoyl
- R g is keto and R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is keto and R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t- butoxycarbonyl or t-amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is hydroxy
- R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is hydroxy and R 14 is hydrido.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t-amyloxycarbonyl, still more preferably t- butoxycarbonyl
- R 2 is benzoyl
- R 9 is acyloxy
- R 14 is hydroxy.
- X 3 is heterocyclo
- X 5 is benzoyl, alkoxycarbonyl, or heterocyclocarbonyl, more preferably benzoyl, t-butoxycarbonyl or t- amyloxycarbonyl, still more preferably t-butoxycarbonyl
- R 2 is benzoyl
- R 9 is acyloxy
- R 14 is hydrido.
- R 7 and R 10 may each have the beta stereochemical configuration
- R 7 and R 10 may each have the alpha stereochemical configuration
- R 7 may have the alpha stereochemical configuration while R 10 has the beta stereochemical configuration
- R 7 may have the beta stereochemical configuration while R 10 has the alpha stereochemical configuration.
- Taxanes having the general formula 1 may be obtained by treatment of a ⁇ -lactam with an alkoxide having the taxane tetracyclic nucleus and a C-13 metallic oxide substituent to form compounds having a ⁇ -amido ester substituent at C-13. (as described more fully in Holton U.S. Patent 5,466,834), followed by removal of the hydroxy protecting groups.
- the ⁇ -lactam has the following structural formula (3):
- Alkoxide 4 may be prepared from 10-deacetylbaccatin III (or a derivative thereof) by selective protection of the C(7) hydroxyl group and then esterification of the C(10) hydroxyl group followed by treatment with a metallic amide.
- the C(7) hydroxyl group of 10- deacetylbaccatin III is selectively protected with a silyl group as described, for example, by Denis, et. al. (J. Am. Chem. Soc, 1988, 110, 5917).
- the silylating agents may be used either alone or in combination with a catalytic amount of a base such as an alkali metal base.
- the C(10) hydroxyl group of a taxane can be selectively acylated in the absence of a base, as described, for example in Holton et al., PCT Patent Application WO 99/09021.
- Acylating agents which may be used for the selective acylation of the C(10) hydroxyl group of a taxane include substituted or unsubstituted alkyl or aryl anhydrides. While the acylation of the C(10) hydroxy group of the taxane will proceed at an adequate rate for many acylating agents, it has been discovered that the reaction rate may be increased by including a Lewis acid in the reaction mixture.
- Preferred Lewis acids include zinc chloride, stannic chloride, cerium trichloride, cuprous chloride, lanthanum trichloride, dysprosium trichloride, and ytterbium trichloride.
- Zinc chloride or cerium trichloride is particularly preferred when the acylating agent is an anhydride.
- Taxane derivatives having acyloxy substituents other than benzoyloxy at C(2) may be prepared, for example, as described in Holton et al., U.S. Patent No.
- Taxanes having acyloxy or hydroxy substituents at C(9) in place of keto may be prepared, for example as described in Holton et al., U.S. Patent No. 6,011 ,056 or Gunawardana et al., U.S. Patent No. 5,352,806.
- Taxanes having a beta hydroxy substituent at C(14) may be prepared from naturally occurring 14-hydroxy-10-deacetylbaccatin III.
- the ⁇ -lactam may be prepared as described in Holton, U.S. Patent No. 5,430,160 and the resulting enatiomeric mixtures of ⁇ -lactams may be resolved by a stereoselective hydrolysis using a lipase or enzyme as described, for example, in Patel, U.S. Patent No. 5,879,929 Patel U.S. Patent No. 5,567,614 or a liver homogenate as described, for example, in PCT Patent Application No. 00/41204.
- the ⁇ -lactam can be prepared as illustrated in the following reaction scheme:
- the beef liver resolution may be carried out, for example, by combining the enatiomeric ⁇ -lactam mixture with a beef liver suspension (prepared, for example, by adding 20 g of frozen beef liver to a blender and then adding a pH 8 buffer to make a total volume of 1 L).
- Compounds of formula 1 of the instant invention are useful for inhibiting tumor growth in mammals including humans and are preferably administered in the form of a pharmaceutical composition comprising an effective antitumor amount of a compound of the instant invention in combination with at least one pharmaceutically or pharmacologically acceptable carrier.
- the carrier also known in the art as an excipient, vehicle, auxiliary, adjuvant, or diluent, is any substance which is pharmaceutically inert, confers a suitable consistency or form to the composition, and does not diminish the therapeutic efficacy of the antitumor compounds.
- the carrier is "pharmaceutically or pharmacologically acceptable" if it does not produce an adverse, allergic or other untoward reaction when administered to a mammal or human, as appropriate.
- compositions containing the antitumor compounds of the present invention may be formulated in any conventional manner. Proper formulation is dependent upon the route of administration chosen.
- compositions of the invention can be formulated for any route of administration so long as the target tissue is available via that route.
- Suitable routes of administration include, but are not limited to, oral, parenteral (e.g., intravenous, intraarterial, subcutaneous, rectal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intraperitoneal, or intrastemal), topical (nasal, transdermal, intraocular), intravesical, intrathecal, enteral, pulmonary, intralymphatic, intracavital, vaginal, transurethral, intradermal, aural, intramammary, buccal, orthotopic, intratracheal, intralesional, percutaneous, endoscopical, transmucosal, sublingual and intestinal administration.
- parenteral e.g., intravenous, intraarterial, subcutaneous, rectal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intraperitoneal, or intrastemal
- topical nasal, transdermal, intraocular
- intravesical, intrathecal enteral
- compositions of the present invention are well known to those of ordinary skill in the art and are selected based upon a number of factors: the particular antitumor compound used, and its concentration, stability and intended bioavailability; the disease, disorder or condition being treated with the composition; the subject, its age, size and general condition; and the route of administration. Suitable carriers are readily determined by one of ordinary skill in the art (see, for example, J. G. Nairn, in: Remington's Pharmaceutical Science (A. Gennaro, ed.), Mack Publishing Co., Easton, Pa., (1985), pp. 1492-1517, the contents of which are incorporated herein by reference).
- compositions are preferably formulated as tablets, dispersible powders, pills, capsules, gelcaps, caplets, gels, liposomes, granules, solutions, suspensions, emulsions, syrups, elixirs, troches, dragees, lozenges, or any other dosage form which can be administered orally.
- Techniques and compositions for making oral dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics. Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981 ); and Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976).
- compositions of the invention for oral administration comprise an effective antitumor amount of a compound of the invention in a pharmaceutically acceptable carrier.
- suitable carriers for solid dosage forms include sugars, starches, and other conventional substances including lactose, talc, sucrose, gelatin, carboxymethylcellulose, agar, mannitol, sorbitol, calcium phosphate, calcium carbonate, sodium carbonate, kaolin, alginic acid, acacia, corn starch, potato starch, sodium saccharin, magnesium carbonate, tragacanth, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, and stearic acid.
- such solid dosage forms may be uncoated or may be coated by known techniques; e.g., to delay disintegration and absorption.
- the antitumor compounds of the present invention are also preferably formulated for parenteral administration, e.g., formulated for injection via intravenous, intraarterial, subcutaneous, rectal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intraperitoneal, or intrastemal routes.
- the compositions of the invention for parenteral administration comprise an effective antitumor amount of the antitumor compound in a pharmaceutically acceptable carrier.
- Dosage forms suitable for parenteral administration include solutions, suspensions, dispersions, emulsions or any other dosage form which can be administered parenterally. Techniques and compositions for making parenteral dosage forms are known in the art.
- Suitable carriers used in formulating liquid dosage forms for oral or parenteral administration include nonaqueous, pharmaceutically-acceptable polar solvents such as oils, alcohols, amides, esters, ethers, ketones, hydrocarbons and mixtures thereof, as well as water, saline solutions, dextrose solutions (e.g., DW5), electrolyte solutions, or any other aqueous, pharmaceutically acceptable liquid.
- nonaqueous, pharmaceutically-acceptable polar solvents such as oils, alcohols, amides, esters, ethers, ketones, hydrocarbons and mixtures thereof, as well as water, saline solutions, dextrose solutions (e.g., DW5), electrolyte solutions, or any other aqueous, pharmaceutically acceptable liquid.
- Suitable nonaqueous, pharmaceutically-acceptable polar solvents include, but are not limited to, alcohols (e.g., ⁇ -glycerol formal, ⁇ -glycerol formal, 1 , 3- butyleneglycol, aliphatic or aromatic alcohols having 2-30 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, t-butanol, hexanol, octanol, amylene hydrate, benzyl alcohol, glycerin (glycerol), glycol, hexylene glycol, tetrahydrofurfuryl alcohol, lauryl alcohol, cetyl alcohol, or stearyl alcohol, fatty acid esters of fatty alcohols such as polyalkylene glycols (e.g., polypropylene glycol, polyethylene glycol), sorbitan, sucrose and cholesterol); amides (e.g., dimethylacetamide (DMA),
- Preferred solvents include those known to stabilize the antitumor compounds, such as oils rich in triglycerides, for example, safflower oil, soybean oil or mixtures thereof, and alkyleneoxy modified fatty acid esters such as polyoxyl 40 hydrogenated castor oil and polyoxyethylated castor oils (e.g., Cremophor® EL solution or Cremophor® RH 40 solution).
- oils rich in triglycerides for example, safflower oil, soybean oil or mixtures thereof
- alkyleneoxy modified fatty acid esters such as polyoxyl 40 hydrogenated castor oil and polyoxyethylated castor oils (e.g., Cremophor® EL solution or Cremophor® RH 40 solution).
- triglycerides include Intralipid® emulsified soybean oil (Kabi-Pharmacia Inc., Sweden), Nutralipid ® emulsion (McGaw, Irvine, California), Liposyn® II 20% emulsion (a 20% fat emulsion solution containing 100 mg safflower oil, 100 mg soybean oil, 12 mg egg phosphatides, and 25 mg glycerin per ml of solution; Abbott Laboratories, Chicago, Illinois), Liposyn® III 2% emulsion (a 2% fat emulsion solution containing 100 mg safflower oil, 100 mg soybean oil, 12 mg egg phosphatides, and 25 mg glycerin per ml of solution; Abbott Laboratories, Chicago, Illinois), natural or synthetic glycerol derivatives containing the docosahexaenoyl group at levels between 25% and 100% by weight based on the total fatty acid content (Dhasco® (from Martek Biosciences Corp., Columbia, MD), DHA
- Ethanol is a preferred solvent for use in dissolving the antitumor compound to form solutions, emulsions, and the like.
- Additional minor components can be included in the compositions of the invention for a variety of purposes well known in the pharmaceutical industry. These components will for the most part impart properties which enhance retention of the antitumor compound at the site of administration, protect the stability of the composition, control the pH, facilitate processing of the antitumor compound into pharmaceutical formulations, and the like.
- each of these components is individually present in less than about 15 weight % of the total composition, more preferably less than about 5 weight %, and most preferably less than about 0.5 weight % of the total composition.
- cryoprotective agents for preventing reprecipitation of the taxane include cryoprotective agents for preventing reprecipitation of the taxane, surface active, wetting or emulsifying agents (e.g., lecithin, polysorbate-80, Tween® 80, pluronic 60, polyoxyethylene stearate ), preservatives (e.g., ethyl-p-hydroxybenzoate), microbial preservatives (e.g., benzyl alcohol, phenol, m-cresol, chlorobutanol, sorbic acid, thimerosal and paraben), agents for adjusting pH or buffering agents (e.g., acids, bases, sodium acetate, sorbitan monolaurate), agents for adjusting osmolarity (e.g., glycerin), thickeners (e.g., aluminum monostearate, sterol
- a pharmaceutical composition of the invention comprises at least one nonaqueous, pharmaceutically acceptable solvent and an antitumor compound having a solubility in ethanol of at least about 100, 200, 300, 400, 500, 600, 700 or 800 mg/ml. While not being bound to a particular theory, it is believed that the ethanol solubility of the antitumor compound may be directly related to its efficacy.
- the antitumor compound can also be capable of being crystallized from a solution. In other words, a crystalline antitumor compound, such as compound 1393, can be dissolved in a solvent to form a solution and then recrystallized upon evaporation of the solvent without the formation of any amorphous antitumor compound.
- the antitumor compound have an ID50 value (i.e, the drug concentration producing 50% inhibition of colony formation) of at least 4, 5, 6, 7, 8, 9, or 10 times less that of paclitaxel when measured according to the protocol set forth in the working examples.
- ID50 value i.e, the drug concentration producing 50% inhibition of colony formation
- Dosage form administration by these routes may be continuous or intermittent, depending, for example, upon the patient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to and assessable by a skilled practitioner.
- Dosage and regimens for the administration of the pharmaceutical compositions of the invention can be readily determined by those with ordinary skill in treating cancer. It is understood that the dosage of the antitumor compounds will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. For any mode of administration, the actual amount of antitumor compound delivered, as well as the dosing schedule necessary to achieve the advantageous effects described herein, will also depend, in part, on such factors as the bioavailability of the antitumor compound, the disorder being treated, the desired therapeutic dose, and other factors that will be apparent to those of skill in the art.
- an effective amount of the antitumor compound, whether administered orally or by another route, is any amount which would result in a desired therapeutic response when administered by that route.
- the compositions for oral administration are prepared in such a way that a single dose in one or more oral preparations contains at least 20 mg of the antitumor compound per m 2 of patient body surface area, or at least 50, 100, 150, 200, 300, 400, or 500 mg of the antitumor compound per m 2 of patient body surface area, wherein the average body surface area for a human is 1.8 m 2 .
- a single dose of a composition for oral administration contains from about 20 to about 600 mg of the antitumor compound per m 2 of patient body surface area, more preferably from about 25 to about 400 mg/m 2, even more preferably, from about 40 to about 300 mg/m 2 , and even more preferably from about 50 to about 200 mg/m 2 .
- the compositions for parenteral administration are prepared in such a way that a single dose contains at least 20 mg of the antitumor compound per m 2 of patient body surface area, or at least 40, 50, 100, 150, 200, 300, 400, or 500 mg of the antitumor compound per m 2 of patient body surface area.
- a single dose in one or more parenteral preparations contains from about 20 to about 500 mg of the antitumor compound per m 2 of patient body surface area, more preferably from about 40 to about 400 mg/m 2, and even more preferably, from about 60 to about 350 mg/m 2 .
- the dosage may vary depending on the dosing schedule which can be adjusted as necessary to achieve the desired therapeutic effect. It should be noted that the ranges of effective doses provided herein are not intended to limit the invention and represent preferred dose ranges. The most preferred dosage will be tailored to the individual subject, as is understood and determinable by one of ordinary skill in the art without undue experimentation.
- the concentration of the antitumor compound in a liquid pharmaceutical composition is preferably between about 0.01 mg and about 10 mg per ml of the composition, more preferably between about 0.1 mg and about 7 mg per ml, even more preferably between about 0.5 mg and about 5 mg per ml, and most preferably between about 1.5 mg and about 4 mg per ml. Relatively low concentrations are generally preferred because the antitumor compound is most soluble in the solution at low concentrations.
- the concentration of the antitumor compound in a solid pharmaceutical composition for oral administration is preferably between about 5 weight % and about 50 weight %, based on the total weight of the composition, more preferably between about 8 weight % and about 40 weight %, and most preferably between about 10 weight % and about 30 weight %.
- solutions for oral administration are prepared by dissolving an antitumor compound in any pharmaceutically acceptable solvent capable of dissolving the compound (e.g., ethanol or methylene chloride) to form a solution.
- a pharmaceutically acceptable solvent capable of dissolving the compound (e.g., ethanol or methylene chloride)
- An appropriate volume of a carrier which is a solution, such as Cremophor® EL solution, is added to the solution while stirring to form a pharmaceutically acceptable solution for oral administration to a patient.
- a pharmaceutically acceptable solution for oral administration e.g., ethanol or methylene chloride
- powders or tablets for oral administration are prepared by dissolving an antitumor compound in any pharmaceutically acceptable solvent capable of dissolving the compound (e.g..ethanol or methylene chloride) to form a solution.
- the solvent can optionally be capable of evaporating when the solution is dried under vacuum.
- An additional carrier can be added to the solution prior to drying, such as Cremophor® EL solution.
- the resulting solution is dried under vacuum to form a glass.
- the glass is then mixed with a binder to form a powder.
- the powder can be mixed with fillers or other conventional tabletting agents and processed to form a tablet for oral administration to a patient.
- the powder can also be added to any liquid carrier as described above to form a solution, emulsion, suspension or the like for oral administration.
- Emulsions for parenteral administration can be prepared by dissolving an antitumor compound in any pharmaceutically acceptable solvent capable of dissolving the compound (e.g., ethanol or methylene chloride) to form a solution.
- An appropriate volume of a carrier which is an emulsion, such as Liposyn® II or Liposyn® III emulsion, is added to the solution while stirring to form a pharmaceutically acceptable emulsion for parenteral administration to a patient.
- emulsions can be formulated to contain a minimal amount of, or to be free of, ethanol or Cremophor® solution, which are known in the art to cause adverse physiological effects when administered at certain concentrations in parenteral formulations.
- Solutions for parenteral administration can be prepared by dissolving an antitumor compound in any pharmaceutically acceptable solvent capable of dissolving the compound (e.g., ethanol or methylene chloride) to form a solution.
- any pharmaceutically acceptable solvent capable of dissolving the compound e.g., ethanol or methylene chloride
- a carrier which is a solution, such as Cremophor® solution
- Cremophor® solution is added to the solution while stirring to form a pharmaceutically acceptable solution for parenteral administration to a patient.
- solutions can be formulated to contain a minimal amount of, or to be free of, ethanol or Cremophor® solution, which are known in the art to cause adverse physiological effects when administered at certain concentrations in parenteral formulations.
- the emulsions or solutions described above for oral or parenteral administration can be packaged in IV bags, vials or other conventional containers in concentrated form and diluted with any pharmaceutically acceptable liquid, such as saline, to form an acceptable taxane concentration prior to use as is known in the art.
- hydrocarbon and “hydrocarbyl” as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to 20 carbon atoms.
- substituted hydrocarbyl moieties described herein are hydrocarbyl moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom.
- substituents include halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers.
- heteroatom shall mean atoms other than carbon and hydrogen.
- the "heterosubstituted methyl” moieties described herein are methyl groups in which the carbon atom is covalently bonded to at least one heteroatom and optionally with hydrogen, the heteroatom being, for example, a nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or halogen atom.
- the heteroatom may, in turn, be substituted with other atoms to form a heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, oxy, acyloxy, nitro, amino, amido, thiol, ketals, acetals, esters or ether moiety.
- heterosubstituted acetate moieties described herein are acetate groups in which the carbon of the methyl group is covalently bonded to at least one heteroatom and optionally with hydrogen, the heteroatom being, for example, a nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or halogen atom.
- the heteroatom may, in turn, be substituted with other atoms to form a heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, oxy, acyloxy, nitro, amino, amido, thiol, ketals, acetals, esters or ether moiety.
- the alkyl groups described herein are preferably lower alkyl containing from one to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, butyl, hexyl and the like.
- the alkenyl groups described herein are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.
- alkynyl groups described herein are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.
- aryl or “ar” as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl.
- halogen or halo as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.
- heterocyclo or “heterocyclic” as used herein alone or as part of another group denote optionally substituted, fully saturated or unsaturated, monocyclic or bicyclic, aromatic or nonaromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring.
- the heterocyclo group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom.
- heterocyclo include heteroaromatics such as furyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like.
- substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.
- heteroaromatic as used herein alone or as part of another group denote optionally substituted aromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring.
- the heteroaromatic group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom.
- Exemplary heteroaromatics include furyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like.
- substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.
- acyl denotes the moiety formed by removal of the hydroxyl group from the group --COOH of an organic carboxylic acid, e.g., RC(O)-, wherein R is R 1 , R 1 O-, R 1 R 2 N-, or R 1 S-, R 1 is hydrocarbyl, heterosubstituted hydrocarbyl, or heterocyclo and R 2 is hydrogen, hydrocarbyl or substituted hydrocarbyl.
- acyloxy denotes an acyl group as described above bonded through an oxygen linkage (-O--), e.g., RC(O)O- wherein R is as defined in connection with the term "acyl.”
- alkoxycarbonyloxy moieties described herein comprise lower hydrocarbon or substituted hydrocarbon or substituted hydrocarbon moieties.
- the carbamoyloxy moieties described herein are derivatives of carbamic acid in which one or both of the amine hydrogens is optionally replaced by a hydrocarbyl, substituted hydrocarbyl or heterocyclo moiety.
- hydroxyl protecting group and "hydroxy protecting group” as used herein denote a group capable of protecting a free hydroxyl group ("protected hydroxyl") which, subsequent to the reaction for which protection is employed, may be removed without disturbing the remainder of the molecule.
- a variety of protecting groups for the hydroxyl group and the synthesis thereof may be found in "Protective Groups in Organic Synthesis" by T. W. Greene, John Wiley and Sons, 1981 , or Fieser & Fieser.
- Exemplary hydroxyl protecting groups include methoxymethyl, 1-ethoxyethyI, benzyloxymethyl, (.beta.-trimethylsilylethoxy)methyl, tetrahydropyranyl, 2,2,2-trichloroethoxycarbonyl, t-butyl(diphenyl)silyl, trialkylsilyl, trichloromethoxycarbonyl and 2,2,2-trichloroethoxymethyl.
- Ac means acetyl
- Bz means benzoyl
- Et means ethyl
- Me means methyl; “Ph” means phenyl; “iPr” means isopropyl; “tBu” and “t-Bu” means tert-butyl; “R” means lower alkyl unless otherwise defined; “py” means pyridine or pyridyl; “TES” means triethylsilyl; “TMS” means trimethylsilyl; “LAH” means lithium aluminum hydride; “10-DAB” means 10-desacetylbaccatin III”; “amine protecting group” includes, but is not limited to, carbamates, for example, 2,2,2-trichloroethylcarbamate or tertbutylcarbamate; “protected hydroxy” means - OP wherein P is a hydroxy protecting group; “tBuOCO” and “BOC” mean tertbutoxycarbonyl; “tAmOCO” means tert-amyloxycarbonyl; “PhCO means phenylcarbonyl”; "
- 10-Propionyl-10-deacetyl baccatin 111 To a mixture of 0.2 g (0.367 mmol) of 10-deacetyl baccatin III and 0.272 g (1.10 mmol) of CeCI 3 in 10 mL of THF at 25 °C was added 2.35 mL (18.36 mmol) of propionic anhydride. After 30 min the reaction mixture was diluted with 200 mL of EtOAc, then washed three times with 50 mL of saturated aqueous NaHCO 3 solution and brine. The organic extract was dried over Na 2 SO 4 and concentrated in vacuo.
- the mixture was washed with 20 mL of saturated aqueous sodium bicarbonate solution and the organic layer separated.
- the aqueous layer was extracted with 30 mL of a 1:1 mixture of ethyl acetate and hexane, and the combined organic extracts were washed with brine, dried over Na 2 SO 4 , and concentrated in vacuo.
- the crude solid was purified by flash column chromatography on silica gel using 50% EtOAc/hexane as eluent to give 0.242 g (99%) of 7-dimethylphenylsilyl-10- propionyl-10-deacetyl baccatin III as a solid.
- Example 2 The procedures described in Example 1 were repeated, but other suitably protected ⁇ -lactams were substituted for the ⁇ -lactam of Example 1 to prepare the series of compounds having structural formula (13) and the combinations of substituents identified in the following table
- Example 3 Following the processes described in Example 1 and elsewhere herein, the following specific taxanes having structural formula 14 may be prepared, wherein R 10 is as previously defined, including wherein R 10 is R 10a COO- and R 10a is (i) substituted or unsubstituted C 2 to C 8 alkyl such as ethyl, or straight, branched or cyclic propyl, butyl, pentyl, or hexyl; (ii) substituted or unsubstituted C 2 to C 8 alkenyl such as ethenyl or straight, branched or cyclic propenyl, butenyl, pentenyl or hexenyl; (iii) substituted or unsubstituted C 2 to C 8 alkynyl such as ethynyl or straight or branched propynyl, butynyl, pentynyl, or hexynyl; (iv) substituted or unsubstituted
- R 10 may be R 10a COO- wherein R 10a is ethyl, straight, branched or cyclic propyl, straight or branched propenyl, isobutenyl, furyl or thienyl.
- Example 4 Following the processes described in Example 1 and elsewhere herein, the following specific taxanes having structural formula 15 may be prepared, wherein R 7 is hydroxy and R 10 in each of the series (that is, each of series "A” through “K”) is as previously defined, including wherein R 10 is R 10a COO- and R 10a is (i) substituted or unsubstituted, preferably unsubstituted, C 2 to C 8 alkyl (straight, branched or cyclic), such as ethyl, propyl, butyl, pentyl, or hexyl; (ii) substituted or unsubstituted, preferably unsubstituted, C 2 to C 8 alkenyl (straight, branched or cyclic), such as ethenyl, propenyl, butenyl, pentenyl or hexenyl; (iii) substituted or unsubstituted, preferably unsubstituted, C 2 to C 8 al
- X 10 is as otherwise as defined herein.
- heterocyclo is substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 7 and R 10 each have the beta stereochemical configuration.
- X 10 and R 2a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 and R 10 each have the beta stereochemical configuration.
- X 10 and R 9a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 9a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 , R 9 and R 10 each have the beta stereochemical configuration.
- X 10 is as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 7 , R 9 (series D only) and R 10 each have the beta stereochemical configuration.
- X 10 , R 2a and R 9a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 , R g and R 10 each have the beta stereochemical configuration.
- X 10 and R 2a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 , R 9 and R 10 each have the beta stereochemical configuration.
- X 10 is as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 and R 10 each have the beta stereochemical configuration.
- X 10 and R 2a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 and R 10 each have the beta stereochemical configuration.
- X 10 and R 2a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 , R 9 and R 10 each have the beta stereochemical configuration.
- X 10 , R 2a and R 9a are as otherwise as defined herein.
- heterocyclo is preferably substituted or unsubstitued furyl, thienyl, or pyridyl
- X 10 is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl (e.g., tert-butyl)
- R 2a is preferably substituted or unsubstitued furyl, thienyl, pyridyl, phenyl, or lower alkyl
- R 7 , R g and R 10 each have the beta stereochemical configuration.
- any substituents of each X 3 , X 5 , R 2 , R 9 , R 10 may be hydrocarbyl or any of the heteroatom containing substituents selected from the group consisting of heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, keto, acyloxy, nitro, amino, amido, thiol, ketal, acetal, ester and ether moieties, but not phosphorous containing moieties.
- HCT116 Four hundred cells (HCT116) were plated in 60 mm Petri dishes containing 2.7 mL of medium (modified McCoy's 5a medium containing 10% fetal bovine serum and 100 units/mL penicillin and 100 g/mL streptomycin). The cells were incubated in a CO2 incubator at 37 °C for 5 h for attachment to the bottom of Petri dishes. The compounds identified in Example 2 were made up fresh in medium at ten times the final concentration, and then 0.3 mL of this stock solution was added to the 2.7 mL of medium in the dish. The cells were then incubated with drugs for 72 h at 37 ° C.
- medium modified McCoy's 5a medium containing 10% fetal bovine serum and 100 units/mL penicillin and 100 g/mL streptomycin
- the drug-containing media were decanted, the dishes were rinsed with 4 mL of Hank's Balance Salt Solution (HBSS), 5 mL of fresh medium was added, and the dishes were returned to the incubator for colony formation. The cell colonies were counted using a colony counter after incubation for 7 days. Cell survival was calculated and the values of ID50 (the drug concentration producing 50% inhibition of colony formation) were determined for each tested compound.
- HBSS Hank's Balance Salt Solution
- Solution 1 Antitumor compound 0499 was dissolved in ethanol to form a solution containing 106 mg of the compound per ml of solution. An equal volume of Cremophor® EL solution was added to the solution while stirring to form a solution containing 53 mg of compound 0499 per ml of solution. This solution was diluted using 9 parts by weight of saline to form a pharmaceutically acceptable solution for administration to a patient.
- Solution 2 Antitumor compound 0550 was dissolved in ethanol to form a solution containing 140 mg of the compound per ml of solution. An equal volume of Cremophor® EL solution was added to the solution while stirring to form a solution containing 70 mg of compound 0550 per ml of solution. This solution was diluted using 9 parts by weight of saline to form a pharmaceutically acceptable solution for administration to a patient.
- Solution 3 Antitumor compound 0611 was dissolved in ethanol to form a solution containing 150 mg of the compound per ml of solution. An equal volume of Cremophor® EL solution was added to the solution while stirring to form a solution containing 75 mg of compound 0611 per ml of solution. This solution was diluted using 9 parts by weight of saline to form a pharmaceutically acceptable solution for administration to a patient.
- Solution 4 Antitumor compound 0748 was dissolved in ethanol to form a solution containing 266 mg of the compound per ml of solution. An equal volume of Cremophor® EL solution was added to the solution while stirring to form a solution containing 133 mg of compound 0748 per ml of solution. This solution was diluted using 9 parts by weight of saline to form a pharmaceutically acceptable solution for administration to a patient.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mechanical Engineering (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002368274A CA2368274C (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
PL351380A PL202957B1 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
AT01906971T ATE432928T1 (en) | 2000-02-02 | 2001-02-02 | C10 TAXANESTERS AS AN ANTITUMOR AGENT |
EP01906971A EP1165553B1 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
IL145638A IL145638A (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
NZ514382A NZ514382A (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
JP2001557864A JP2003522172A (en) | 2000-02-02 | 2001-02-02 | C10 ester-substituted taxanes as antitumor agents |
HU0600302A HUP0600302A2 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
DE60138853T DE60138853D1 (en) | 2000-02-02 | 2001-02-02 | C10-TAXANESTER AS ANTITUMOR |
BR0104354-4A BR0104354A (en) | 2000-02-02 | 2001-02-02 | Taxanes replaced with c10 ester |
UA2001106733A UA75039C2 (en) | 2000-02-02 | 2001-02-02 | Taxanes having an ester substituent at c10, pharmaceutical composition based thereon and a method for inhibiting tumors growth |
MXPA01009905A MXPA01009905A (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents. |
SK1369-2001A SK13692001A3 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
AU34809/01A AU782150B2 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
ROA200101083A RO121270B1 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes to be used as antitumour agents |
NO20014754A NO327910B1 (en) | 2000-02-02 | 2001-10-01 | Taxanes, pharmaceutical compositions comprising these, oral administration preparations comprising the taxanes, and use of the taxanes for the preparation of oral pharmaceutical preparations for inhibition of tumor growth in mammals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17978200P | 2000-02-02 | 2000-02-02 | |
US60/179,792 | 2000-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001057032A1 true WO2001057032A1 (en) | 2001-08-09 |
Family
ID=22657972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/003623 WO2001057032A1 (en) | 2000-02-02 | 2001-02-02 | C10 ester substituted taxanes as antitumor agents |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1165553B1 (en) |
JP (1) | JP2003522172A (en) |
CN (1) | CN1380882A (en) |
AT (1) | ATE432928T1 (en) |
AU (1) | AU782150B2 (en) |
BG (1) | BG64889B1 (en) |
BR (1) | BR0104354A (en) |
CA (1) | CA2368274C (en) |
CZ (1) | CZ20013430A3 (en) |
DE (1) | DE60138853D1 (en) |
GE (1) | GEP20043323B (en) |
HU (1) | HUP0600302A2 (en) |
IL (1) | IL145638A (en) |
MX (1) | MXPA01009905A (en) |
NO (1) | NO327910B1 (en) |
NZ (1) | NZ514382A (en) |
PL (1) | PL202957B1 (en) |
RO (1) | RO121270B1 (en) |
RU (1) | RU2262506C2 (en) |
SK (1) | SK13692001A3 (en) |
TR (1) | TR200102858T1 (en) |
TW (1) | TWI299732B (en) |
UA (1) | UA75039C2 (en) |
WO (1) | WO2001057032A1 (en) |
ZA (1) | ZA200108055B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003055360A (en) * | 2001-07-31 | 2003-02-26 | Florida State Univ Research Foundation Inc | C10 ester-substituted taxane |
US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
SG129990A1 (en) * | 2001-08-01 | 2007-03-20 | Univ Florida State Res Found | C10 ester substituted taxanes |
EP1848423A2 (en) * | 2005-02-14 | 2007-10-31 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
US7589111B2 (en) | 2004-02-13 | 2009-09-15 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
WO2009145981A1 (en) * | 2008-03-31 | 2009-12-03 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534709A1 (en) * | 1991-09-23 | 1993-03-31 | Florida State University | Substituted taxanes as antitumour agents |
US5243045A (en) * | 1991-09-23 | 1993-09-07 | Florida State University | Certain alkoxy substituted taxanes and pharmaceutical compositions containing them |
WO1996013495A1 (en) * | 1994-10-28 | 1996-05-09 | The Research Foundation Of State University Of New York | Taxoid derivatives, their preparation and their use as antitumor agents |
WO1997032578A1 (en) * | 1996-03-04 | 1997-09-12 | The Research Foundation Of State University Of New York | Taxoid anti-tumor agents and pharmaceutical compositions thereof |
WO1997044026A1 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
WO1997044063A2 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Dha-pharmaceutical agent conjugates |
WO2000053592A1 (en) * | 1999-03-05 | 2000-09-14 | Asahi Kasei Kabushiki Kaisha | Osteogenesis promoters |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (en) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
IL108443A0 (en) * | 1993-01-29 | 1994-04-12 | Univ Florida State | C7 taxane derivatives and pharmaceutical compositions containing them |
ATE209489T1 (en) * | 1993-03-22 | 2001-12-15 | Univ Florida State | TAXANES WITH PYRIDYL-SUBSTITUTED SIDE CHAIN |
DK1260223T3 (en) * | 1993-03-22 | 2005-09-05 | Univ Florida State | Furyl or thienyl substituted side chain taxanes |
ES2149871T3 (en) * | 1993-03-22 | 2000-11-16 | Univ Florida State | TAXANES THAT HAVE A SIDE CHAIN OF AMINO SUBSTITUTION. |
KR100551945B1 (en) * | 1997-12-19 | 2006-02-20 | 가부시키가이샤 야쿠루트 혼샤 | Taxane derivatives |
-
2001
- 2001-02-02 CA CA002368274A patent/CA2368274C/en not_active Expired - Fee Related
- 2001-02-02 UA UA2001106733A patent/UA75039C2/en unknown
- 2001-02-02 MX MXPA01009905A patent/MXPA01009905A/en active IP Right Grant
- 2001-02-02 AU AU34809/01A patent/AU782150B2/en not_active Ceased
- 2001-02-02 RO ROA200101083A patent/RO121270B1/en unknown
- 2001-02-02 HU HU0600302A patent/HUP0600302A2/en unknown
- 2001-02-02 RU RU2001129501/04A patent/RU2262506C2/en active
- 2001-02-02 NZ NZ514382A patent/NZ514382A/en unknown
- 2001-02-02 EP EP01906971A patent/EP1165553B1/en not_active Expired - Lifetime
- 2001-02-02 TR TR2001/02858T patent/TR200102858T1/en unknown
- 2001-02-02 DE DE60138853T patent/DE60138853D1/en not_active Expired - Lifetime
- 2001-02-02 CZ CZ20013430A patent/CZ20013430A3/en unknown
- 2001-02-02 GE GE4523A patent/GEP20043323B/en unknown
- 2001-02-02 BR BR0104354-4A patent/BR0104354A/en not_active IP Right Cessation
- 2001-02-02 JP JP2001557864A patent/JP2003522172A/en active Pending
- 2001-02-02 SK SK1369-2001A patent/SK13692001A3/en unknown
- 2001-02-02 AT AT01906971T patent/ATE432928T1/en not_active IP Right Cessation
- 2001-02-02 PL PL351380A patent/PL202957B1/en not_active IP Right Cessation
- 2001-02-02 CN CN01800568A patent/CN1380882A/en active Pending
- 2001-02-02 IL IL145638A patent/IL145638A/en not_active IP Right Cessation
- 2001-02-02 WO PCT/US2001/003623 patent/WO2001057032A1/en active Application Filing
- 2001-03-27 TW TW090102238A patent/TWI299732B/en not_active IP Right Cessation
- 2001-10-01 ZA ZA200108055A patent/ZA200108055B/en unknown
- 2001-10-01 BG BG105965A patent/BG64889B1/en unknown
- 2001-10-01 NO NO20014754A patent/NO327910B1/en not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0534709A1 (en) * | 1991-09-23 | 1993-03-31 | Florida State University | Substituted taxanes as antitumour agents |
US5243045A (en) * | 1991-09-23 | 1993-09-07 | Florida State University | Certain alkoxy substituted taxanes and pharmaceutical compositions containing them |
US5250683A (en) * | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
WO1996013495A1 (en) * | 1994-10-28 | 1996-05-09 | The Research Foundation Of State University Of New York | Taxoid derivatives, their preparation and their use as antitumor agents |
WO1997032578A1 (en) * | 1996-03-04 | 1997-09-12 | The Research Foundation Of State University Of New York | Taxoid anti-tumor agents and pharmaceutical compositions thereof |
WO1997044026A1 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere |
WO1997044063A2 (en) * | 1996-05-22 | 1997-11-27 | Neuromedica, Inc. | Dha-pharmaceutical agent conjugates |
WO2000053592A1 (en) * | 1999-03-05 | 2000-09-14 | Asahi Kasei Kabushiki Kaisha | Osteogenesis promoters |
Non-Patent Citations (6)
Title |
---|
B.-X. SHI ET AL.: "Sudies on the Quantitative Structure-activity Relationships of Paclitaxel Analogues", GAODENG XUEXIAO HUAXUE XUEBAO, vol. 21, no. 3, 2000, pages 401 - 406, XP000999959 * |
I. OJIMA ET AL.: "Enantiopure fluorine-containing taxoids: potent anticancer agents and versatile probes for biomedical problems", J. FLUORINE CHEM., vol. 97, no. 1-2, 1999, pages 3 - 10, XP004172067 * |
I. OJIMA ET AL.: "Synthesis and biological activity of novel 3'-trifluoromethyl taxoids", BIOORG. MED. CHEM. LETT., vol. 7, no. 2, 1997, pages 133 - 138, XP004135981 * |
I. OJIMA ET AL.: "Synthesis and structure-activity relationships of new second-generation taxoids", BIOORG. MED. CHEM. LETT., vol. 9, no. 24, 1999, pages 3423 - 3428, XP004185527 * |
J. DUBOIS ET AL.: "Fluorescent and Biotinylated Analogues of Docetaxel: Synthesis and Biological Evaluation", BIOORG. MED. CHEM. LETT., vol. 3, no. 10, 1995, pages 1357 - 1368, XP000999888 * |
J. KANT ET AL.: "A Chemoselective Approach to Functionalize the C-10 Position of 10-Deacetylbaccatin III. Synthesis and Biological Properties of Novel C-10 Taxol (R) Analogues", TETRAHEDRON LETT., vol. 35, no. 31, 1994, pages 5543 - 5546, XP002915065 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649632B2 (en) | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
US7524869B2 (en) | 2000-02-02 | 2009-04-28 | Florida State University Research Foundation, Inc. | Taxanes having a C10 ester substituent |
JP2003055360A (en) * | 2001-07-31 | 2003-02-26 | Florida State Univ Research Foundation Inc | C10 ester-substituted taxane |
EP1285920A1 (en) * | 2001-07-31 | 2003-02-26 | Florida State University Research Foundation, Inc. | C10 Ester sustituted taxanes as antitumor agents |
SG129990A1 (en) * | 2001-08-01 | 2007-03-20 | Univ Florida State Res Found | C10 ester substituted taxanes |
US7589111B2 (en) | 2004-02-13 | 2009-09-15 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
US8003812B2 (en) | 2004-02-13 | 2011-08-23 | Florida State University Research Foundation, Inc. | C10 cyclopentyl ester substituted taxanes |
EP1848423A2 (en) * | 2005-02-14 | 2007-10-31 | Florida State University Research Foundation, Inc. | C10 cyclopropyl ester substituted taxane compositions |
EP1848423A4 (en) * | 2005-02-14 | 2008-12-31 | Univ Florida State Res Found | C10 cyclopropyl ester substituted taxane compositions |
WO2009145981A1 (en) * | 2008-03-31 | 2009-12-03 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes |
US8242166B2 (en) | 2008-03-31 | 2012-08-14 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes |
Also Published As
Publication number | Publication date |
---|---|
BR0104354A (en) | 2002-01-02 |
CZ20013430A3 (en) | 2002-04-17 |
UA75039C2 (en) | 2006-03-15 |
AU782150B2 (en) | 2005-07-07 |
BG105965A (en) | 2002-07-31 |
PL202957B1 (en) | 2009-08-31 |
CA2368274A1 (en) | 2001-08-09 |
MXPA01009905A (en) | 2003-08-20 |
GEP20043323B (en) | 2004-02-10 |
HUP0600302A2 (en) | 2006-07-28 |
PL351380A1 (en) | 2003-04-07 |
EP1165553A1 (en) | 2002-01-02 |
CN1380882A (en) | 2002-11-20 |
IL145638A0 (en) | 2002-06-30 |
SK13692001A3 (en) | 2002-07-02 |
DE60138853D1 (en) | 2009-07-16 |
EP1165553B1 (en) | 2009-06-03 |
CA2368274C (en) | 2009-10-13 |
NO20014754L (en) | 2001-11-29 |
BG64889B1 (en) | 2006-08-31 |
RU2262506C2 (en) | 2005-10-20 |
NZ514382A (en) | 2004-05-28 |
RO121270B1 (en) | 2007-02-28 |
ATE432928T1 (en) | 2009-06-15 |
JP2003522172A (en) | 2003-07-22 |
ZA200108055B (en) | 2003-12-01 |
TWI299732B (en) | 2008-08-11 |
AU3480901A (en) | 2001-08-14 |
TR200102858T1 (en) | 2002-12-23 |
NO327910B1 (en) | 2009-10-19 |
NO20014754D0 (en) | 2001-10-01 |
IL145638A (en) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2368993C (en) | C7 ester substituted taxanes as antitumor agents | |
US20070249707A1 (en) | Taxanes having c7 hydroxy and c10 heterosubstituted acetate substituents | |
US20050143446A1 (en) | C7 heterosubstituted acetate taxane compositions | |
US6660866B2 (en) | C10 carbonate substituted taxanes | |
US6649632B2 (en) | C10 ester substituted taxanes | |
EP1165553B1 (en) | C10 ester substituted taxanes as antitumor agents | |
EP1165551B1 (en) | C10 carbamoyloxy substituted taxanes as antitumor agents | |
WO2001057030A1 (en) | C7 carbonate substituted taxanes as antitumor agents | |
US20030060638A1 (en) | C7 carbamate substituted taxanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 01800568.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2368274 Country of ref document: CA Ref document number: 2368274 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 34809/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 514382 Country of ref document: NZ Ref document number: PV2001-3430 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13692001 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/1335/CHE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017012591 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 105965 Country of ref document: BG Kind code of ref document: A Ref document number: 2001 557864 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/08055 Country of ref document: ZA Ref document number: PA/a/2001/009905 Country of ref document: MX Ref document number: 200108055 Country of ref document: ZA Ref document number: 2001/02858 Country of ref document: TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001906971 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200101066 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001906971 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-3430 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |